The estimated Net Worth of Badreddin Edris is at least $16.8 Milion dollars as of 3 September 2024. Badreddin Edris owns over 20,000 units of SpringWorks Therapeutics stock worth over $8,876,336 and over the last 5 years he sold SWTX stock worth over $7,035,840. In addition, he makes $910,430 as Chief Business Officer at SpringWorks Therapeutics.
Badreddin has made over 4 trades of the SpringWorks Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of SWTX stock worth $813,000 on 3 September 2024.
The largest trade he's ever made was selling 32,000 units of SpringWorks Therapeutics stock on 1 July 2021 worth over $2,731,200. On average, Badreddin trades about 9,455 units every 120 days since 2020. As of 3 September 2024 he still owns at least 229,600 units of SpringWorks Therapeutics stock.
You can see the complete history of Badreddin Edris stock trades at the bottom of the page.
DR. Badreddin Edris Ph.D. serves as Chief Business Officer of the Company. Dr. Edris was an investment and operating professional on the private equity team at OrbiMed Advisors LLC, a healthcare investment firm, from June 2014 to November 2018. During his tenure at OrbiMed, Dr. Edris focused on investing in private and public biopharmaceutical companies, and also co-founded and held operating roles at two OrbiMed portfolio companies, Silverback Therapeutics, Inc., where he was Chief Business Officer from April 2016 to September 2018, and Edgewise Therapeutics, Inc. where he was Chief Operating Officer from May 2017 until March 2018. Before OrbiMed, Dr. Edris was a management consultant in the healthcare practice at Bain & Co Inc. Dr. Edris holds a Ph.D. in Genetics from Stanford University School of Medicine, where he was a National Science Foundation Graduate Research Fellow, an M.S. in Biology from Stanford University and a Bachelor’s degree in Microbiology from Weber State University.
As the Chief Business Officer of SpringWorks Therapeutics, the total compensation of Badreddin Edris at SpringWorks Therapeutics is $910,430. There are 3 executives at SpringWorks Therapeutics getting paid more, with Saqib Islam having the highest compensation of $3,284,920.
Badreddin Edris is 53, he's been the Chief Business Officer of SpringWorks Therapeutics since 2017. There are 12 older and 6 younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics, Inc. is Freda Lewis-Hall, 65, who is the Independent Director.
Badreddin's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD, CT, 06902.
Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves... oraz Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
SpringWorks Therapeutics executives and other stock owners filed with the SEC include: